The Inhibition of Receptor-mediated and Voltage-dependent Calcium Entry by the Antiproliferative L-651,582
Overview
Affiliations
L-651,582, 5-amino-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4- carboxamide, an antiproliferative and antiparasitic agent previously shown to affect 45Ca2+ uptake into mammalian cells, inhibits both receptor-mediated and voltage-dependent calcium entry in well characterized in vitro systems. Indo 1 fluorescence measurements of cytosolic calcium levels indicate that the drug has no effect on the initial transient release of internal stores of calcium stimulated by fMet-Leu-Phe in rat polymorphonuclear leukocytes. It does decrease the levels maintained subsequently, however, indicating blockage of calcium influx through receptor-operated channels. L-651,582 also blocks the stimulation of leukotriene B4 (LTB4) production by fMet-Leu-Phe with an IC50 = 0.5 micrograms/ml equal to that for calcium entry inhibition. The LTB4 inhibition is likely due to calcium entry inhibition since L-651,582 does not inhibit calmodulin or enzymes producing arachidonate metabolites. L-651,582 also inhibits potassium-stimulated 45Ca2+ influx into GH3 cells with an IC50 of 0.5 microgram/ml, indicating a block of voltage-gated L-type calcium channels. Patch voltage clamp measurements of current through L- and T-type calcium in guinea pig atrial cells also indicate that L-651,582 is a calcium antagonist. Block of L-type calcium channels is voltage-dependent, and the apparent dissociation constant for the high affinity state is 0.2 micrograms/ml. The IC50 for block of T-type calcium channels is 1.4 micrograms/ml. The inhibition of cellular proliferation and the production of arachidonate metabolites by L-651,582 may be the result of the nearly equipotent block of receptor-operated and voltage-gated calcium channels.
Calcium signalling pathways in prostate cancer initiation and progression.
Silvestri R, Nicoli V, Gangadharannambiar P, Crea F, Bootman M Nat Rev Urol. 2023; 20(9):524-543.
PMID: 36964408 DOI: 10.1038/s41585-023-00738-x.
Shestakova E, Ilyasov S, Shchurova I, Glukhacheva V, Ilyasov D, Zhukov E Pharmaceuticals (Basel). 2022; 15(12).
PMID: 36558894 PMC: 9781658. DOI: 10.3390/ph15121443.
Development of Store-Operated Calcium Entry-Targeted Compounds in Cancer.
Liang X, Zhang N, Pan H, Xie J, Han W Front Pharmacol. 2021; 12:688244.
PMID: 34122115 PMC: 8194303. DOI: 10.3389/fphar.2021.688244.
ORAI1 Ca Channel as a Therapeutic Target in Pathological Vascular Remodelling.
Shawer H, Norman K, Cheng C, Foster R, Beech D, Bailey M Front Cell Dev Biol. 2021; 9:653812.
PMID: 33937254 PMC: 8083964. DOI: 10.3389/fcell.2021.653812.
Bashetti N, Kumar J, Seelam N, Prasanna B, Mintz A, Damuka N Bioorg Med Chem Lett. 2019; 29(23):126707.
PMID: 31630858 PMC: 9214832. DOI: 10.1016/j.bmcl.2019.126707.